ATL1101 suppresses tumours in prostate cancer animal study Oct 15, 2008
Page 1 of 3 15 th October 2008 ATL1101 suppresses tumour growth in key mouse models of prostate cancer Significant suppression of human prostate tumour growth in mouse model of prostate cancer Data highlights unique mechanism of action of ATL1101 Results to be presented Friday 17 th October 2008 at New York Academy of Sciences Annual Meeting of the Oligonucleotide Therapeutics Society, Harvard Conference Center, Boston Antisense Therapeutics (ANP) is pleased to report positive results from... (Sydney Morning Herald)
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis Sep 22, 2008
Conference abstract follows: VLA-4 Antisense - An Oligonucleotide targeting VLA-4 mRNA (ATL1102) significantly reduces new active lesions in patients with RR-MS Volker Limmroth(1), Frederik Barkhof(2), Nuket Desem(3) (1) Department of Neurology, Cologne City Hospitals, University of Cologne, Cologne, Germany, (2) Department of Radiology, MS Center Amsterdam, VU University Medical Center, Amsterdam, Netherlands, (3) Antisense Therapeutics Ltd, Melbourne, VIC, Australia. Background: Antisense... (PR Newswire)
Brain-Derived Neurotrophic Factor and Obesity in WAGR Syndrome Aug 28, 2008
The extent of each deletion was determined with the use of oligonucleotide comparative genomic hybridization. Results Deletions of chromosome 11p in the patients studied ranged from 1. (New England Journal of Medicine)
Bioniche Presents Pre-Clinical Research at Two International Conferences May 24, 2008
The presentation, entitled, "Mycobacteria-derived immunopotentiating molecules and their application in vaccine development", was made by Dr. Nigel C. Phillips, Chief Scientific Officer of Bioniche Life Sciences Inc. Dr. Phillips discussed the development pathway from MCC to the Company's synthetic oligonucleotides, and reviewed their immune stimulatory and immune adjuvant activity. "The data presented clearly demonstrate that the Company's proprietary, synthetic, non-CpG containing... (PR Newswire)
BioMs Medical to present at TIDES(R) Conference May 13, 2008
Toronto Stock Exchange Symbol: MS EDMONTON, May 13 /CNW/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Dr. Mark Krantz, Vice President Scientific Affairs, BioMS Medical, will present at the TIDES(R) - Oligonucleotide and Peptide Technology and Product Development Conference in Las Vegas. About TIDES(R) Conference ------------------------- TIDES(R) is the only forum that covers manufacturing, formulation, delivery, process... (Canada Newswire)
Scientists identify genomic 'fingerprint' for alcohol-induced heart failure May 5, 2008
They analyzed an array containing 1,143 heart-specific oligonucleotide probes that is normally used to screen ribonucleic acid (RNA) samples from transplant recipients and organ donors with alcohol-related heart failure. The researchers then compared messenger RNA (mRNA) from the hearts of persons with alcohol-related heart failure with mRNA from the hearts of persons who did not engage in excessive drinking. (EurekAlert!)
Genetic Diagnostics Expert, Dr. Kavita Reddy, Joins CombiMatrix as Laboratory Director Feb 15, 2008
The technologies we have developed include a platform technology to rapidly produce customizable, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. (Primezone Releases)
Duchenne's Muscular Dystrophy Advance? Dec 28, 2007
In the test tube, a compound called an antisense oligonucleotide partially corrects this genetic misreading. It seems to work in animals. (CBS News)
Local Dystrophin Restoration with PRO051 Dec 27, 2007
NEJM -- Local Dystrophin Restoration with Antisense Oligonucleotide PRO051 ... Local Dystrophin Restoration with Antisense Oligonucleotide PRO051 ... We explored the safety, adverse-event profile, and local dystrophin-restoring effect of a single, intramuscular dose of an antisense oligonucleotide, PRO051, in patients with this disease. (New England Journal of Medicine)
A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols Sep 5, 2007
The method, called the oligonucleotide ligation assay (OLA), will be useful for identifying individuals with disease-related mutations and other genetic variants. It was contributed by Dr. Stuart Macdonald from the University of Kansas (). (EurekAlert!)
Mouse genome will help identify causes of environmental disease Jul 30, 2007
The technology used, the oligonucleotide array, was also used to discover common DNA variation in the human genome. The arrays looked at about 1. (EurekAlert!)
ADA Conference Presentations Highlight Isis' Metabolic Disease Program Research Activities Jun 25, 2007
"In our pipeline we have ISIS 113715, a novel insulin sensitizer targeting PTP-1B which may also promote weight loss. In addition, we have ISIS 325568, targeting glucagon receptor, which inhibits glucagon action in the liver and has additional potentially disease-modifying effects in the pancreas. And we have ISIS 377131, targeting glucocorticoid receptor selectively in liver and fat, which has multiple metabolic effects in addition to lowering glucose such as anti-obesity and lipid-lowering... (PR Newswire)
Who is Robert Cooksey? Jun 22, 2007
In the two papers, researchers identified strains from more than 90 countries using spacer oligonucleotide typing, a new and faster method that uses PCR amplification to detect M. tuberculosis isolates and identify related strains in a much shorter time period than previous techniques. The two studies built on each other to describe TB genotype diversity. (The Scientist)
Tekmira Pharmaceuticals Provides Operational Update at AGM Jun 20, 2007
Tekmira's internal development is focused on novel oligonucleotide drugs. Oligonucleotides are short sequences of deoxyribonucleic acid, or DNA, and ribonucleic acid, or RNA. DNA and RNA are the molecules that determine the genetic building plan of any organism ... Oligonucleotide drugs can treat disease by either stimulating the body's immune system or by switching off genes that produce disease-causing proteins. (CCNMatthews Press Releases)
CoDa Therapeutics Secures $10.0 Million in Additional Series A Financing Feb 22, 2007
"This is a very exciting opportunity, for investors and patients alike, and we believe that CoDa's first clinical indication, enhancement of healing following photorefractive keratectomy (PRK), is an ideal initial ocular indication to demonstrate the ability of its lead drug candidate, Nexagon(TM), to increase the rate of re-epithelialization while potentially reducing inflammation and scarring." About Nexagon(TM) CoDa's technology includes the company's lead drug product Nexagon(TM), a patented... (PR Newswire)
New Technique Assesses Effects Of Multiple Copies Of Genes On Disease Risk Feb 1, 2007
Nimblegen's technique for rapid analysis is known as oligonucleotide array comparative genomic hybridization. "The copy number variants we describe in this paper are numerous and fairly large they vary in length between two thousand and two million DNA base pairs," Graubert says. (Science Daily)
